We are proud to announce that we will exhibit at the Osaka Healthcare Pavilion ……
We are pleased to announce that we have successfully completed the first shipme……
Stella Pharma Concludes MOU on Boron Neutron Capture Therapy System with Fujita Health University, Atransen Pharma, SHI, and Fujita
Stella Pharma Corporation has concluded a Memorandum of Understanding (MOU) to ……
Paper published: Poly(vinyl alcohol) Potentiating an Inert D-Amino Acid-Based Drug for Boron Neutron Capture Therapy
The paper titled “Poly(vinyl alcohol) potentiating an inert D-amino acid-based ……
Paper published: Research on Combination of Proton Beam Therapy and Boron Nuclear Capture Reaction
The Paper titled “Increased cell killing effect in neutron capture enhanced pro……
Conclusion of an Agreement with the National Cancer Center, Sumitomo Heavy Industries, Ltd. and CICS, Inc. for Clinical Trial of BNCT
Stella Pharma announces that it has signed an agreement with the National Cance……
Paper published: Research on Combination Therapy of BNCT and Immune Checkpoint Inhibitors
The Paper “Overcoming immunotherapy resistance and inducing abscopal effects wi……
Application for Orphan Drug Designation: Borofalan (10B) for Recurrent Malignant Glioma and Recurrent Meningioma
Stella Pharma announces that it has applied to the Japanese Ministry of Health,……
The paper “Efficacy and safety of boron neutron capture therapy for Hypopharyng……
Treatment results of unresectable, locally recurrent or locally advanced head and neck cancer published
A paper containing the treatment results of unresectable, locally recurrent or ……
Orphan Drug designation for Borofalan (10B) (SPM-011) as treatment of Cutaneous Angiosarcoma
Angiosarcoma is a kind of cancer that is derived from vascular endothelial cell……
Encounter with Director of Cancer Research Center of Lyon, and Team of Centre Léon Bérard at French Embassy
Business France Japan Office of the French Embassy in Japan engages in building……